EVEREST MEDICINES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.05 HKD | -1.07% |
|
-1.28% | +10.29% |
| 05-14 | Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise | MT |
| 05-14 | Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 956M | - | |||||
| 90.27B | ||||||
| 40.12B | ||||||
| 31.75B | ||||||
| 26.6B | ||||||
| 14.41B |
